vs
Side-by-side financial comparison of Karyopharm Therapeutics Inc. (KPTI) and RxSight, Inc. (RXST). Click either name above to swap in a different company.
Karyopharm Therapeutics Inc. is the larger business by last-quarter revenue ($34.1M vs $32.6M, roughly 1.0× RxSight, Inc.). RxSight, Inc. runs the higher net margin — -28.1% vs -299.9%, a 271.8% gap on every dollar of revenue. On growth, Karyopharm Therapeutics Inc. posted the faster year-over-year revenue change (11.6% vs -18.9%). Over the past eight quarters, RxSight, Inc.'s revenue compounded faster (5.1% CAGR vs 1.4%).
RxSight, Inc. is a medical technology company focused on developing and commercializing innovative intraocular lens solutions for patients undergoing cataract and refractive lens exchange procedures. Its flagship Light Adjustable Lens allows post-surgery power adjustment via a dedicated light delivery device, serving global ophthalmology care markets to improve post-operative visual outcomes for patients.
KPTI vs RXST — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $34.1M | $32.6M |
| Net Profit | $-102.2M | $-9.2M |
| Gross Margin | — | 77.5% |
| Operating Margin | -52.4% | -34.8% |
| Net Margin | -299.9% | -28.1% |
| Revenue YoY | 11.6% | -18.9% |
| Net Profit YoY | -232.0% | -54.1% |
| EPS (diluted) | $-7.02 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $34.1M | $32.6M | ||
| Q3 25 | $44.0M | $30.3M | ||
| Q2 25 | $37.9M | $33.6M | ||
| Q1 25 | $30.0M | $37.9M | ||
| Q4 24 | $30.5M | $40.2M | ||
| Q3 24 | $38.8M | $35.3M | ||
| Q2 24 | $42.8M | $34.9M | ||
| Q1 24 | $33.1M | $29.5M |
| Q4 25 | $-102.2M | $-9.2M | ||
| Q3 25 | $-33.1M | $-9.8M | ||
| Q2 25 | $-37.3M | $-11.8M | ||
| Q1 25 | $-23.5M | $-8.2M | ||
| Q4 24 | $-30.8M | $-5.9M | ||
| Q3 24 | $-32.1M | $-6.3M | ||
| Q2 24 | $23.8M | $-6.1M | ||
| Q1 24 | $-37.4M | $-9.1M |
| Q4 25 | — | 77.5% | ||
| Q3 25 | — | 79.9% | ||
| Q2 25 | — | 74.9% | ||
| Q1 25 | — | 74.8% | ||
| Q4 24 | — | 71.6% | ||
| Q3 24 | — | 71.4% | ||
| Q2 24 | — | 69.5% | ||
| Q1 24 | — | 70.1% |
| Q4 25 | -52.4% | -34.8% | ||
| Q3 25 | -34.6% | -40.1% | ||
| Q2 25 | -64.3% | -41.6% | ||
| Q1 25 | -110.8% | -28.2% | ||
| Q4 24 | -102.4% | -21.5% | ||
| Q3 24 | -67.8% | -26.1% | ||
| Q2 24 | -65.7% | -23.9% | ||
| Q1 24 | -101.9% | -36.2% |
| Q4 25 | -299.9% | -28.1% | ||
| Q3 25 | -75.2% | -32.4% | ||
| Q2 25 | -98.2% | -35.0% | ||
| Q1 25 | -78.2% | -21.6% | ||
| Q4 24 | -100.8% | -14.8% | ||
| Q3 24 | -82.7% | -17.9% | ||
| Q2 24 | 55.6% | -17.4% | ||
| Q1 24 | -112.8% | -30.8% |
| Q4 25 | $-7.02 | $-0.22 | ||
| Q3 25 | $-3.82 | $-0.24 | ||
| Q2 25 | $-4.32 | $-0.29 | ||
| Q1 25 | $-2.77 | $-0.20 | ||
| Q4 24 | $-2.33 | $-0.14 | ||
| Q3 24 | $-3.85 | $-0.16 | ||
| Q2 24 | $-2.97 | $-0.16 | ||
| Q1 24 | $-4.85 | $-0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $60.5M | $228.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-292.9M | $275.7M |
| Total Assets | $108.4M | $311.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $60.5M | $228.1M | ||
| Q3 25 | $37.7M | $227.5M | ||
| Q2 25 | $38.7M | $227.5M | ||
| Q1 25 | $38.8M | $229.3M | ||
| Q4 24 | $62.5M | $237.2M | ||
| Q3 24 | $72.8M | $237.1M | ||
| Q2 24 | $84.8M | $233.3M | ||
| Q1 24 | $30.6M | $125.4M |
| Q4 25 | $-292.9M | $275.7M | ||
| Q3 25 | $-269.3M | $276.0M | ||
| Q2 25 | $-238.9M | $278.0M | ||
| Q1 25 | $-205.9M | $279.3M | ||
| Q4 24 | $-186.0M | $281.2M | ||
| Q3 24 | $-159.6M | $277.3M | ||
| Q2 24 | $-132.1M | $275.2M | ||
| Q1 24 | $-169.0M | $163.9M |
| Q4 25 | $108.4M | $311.8M | ||
| Q3 25 | $96.2M | $308.5M | ||
| Q2 25 | $104.9M | $309.0M | ||
| Q1 25 | $127.7M | $313.0M | ||
| Q4 24 | $164.4M | $318.6M | ||
| Q3 24 | $189.5M | $310.5M | ||
| Q2 24 | $214.0M | $305.5M | ||
| Q1 24 | $204.5M | $183.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.8M | $-1.1M |
| Free Cash FlowOCF − Capex | — | $-2.3M |
| FCF MarginFCF / Revenue | — | -6.9% |
| Capex IntensityCapex / Revenue | 0.0% | 3.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-19.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-11.8M | $-1.1M | ||
| Q3 25 | $-5.9M | $-1.2M | ||
| Q2 25 | $-18.7M | $-4.4M | ||
| Q1 25 | $-39.0M | $-8.8M | ||
| Q4 24 | $-25.8M | $-4.3M | ||
| Q3 24 | $-19.5M | $650.0K | ||
| Q2 24 | $-38.5M | $-4.0M | ||
| Q1 24 | $-43.7M | $-9.3M |
| Q4 25 | — | $-2.3M | ||
| Q3 25 | — | $-1.8M | ||
| Q2 25 | — | $-5.9M | ||
| Q1 25 | — | $-9.4M | ||
| Q4 24 | $-25.9M | $-5.1M | ||
| Q3 24 | — | $-453.0K | ||
| Q2 24 | — | $-5.5M | ||
| Q1 24 | $-43.9M | $-11.3M |
| Q4 25 | — | -6.9% | ||
| Q3 25 | — | -5.8% | ||
| Q2 25 | — | -17.6% | ||
| Q1 25 | — | -24.8% | ||
| Q4 24 | -84.7% | -12.7% | ||
| Q3 24 | — | -1.3% | ||
| Q2 24 | — | -15.9% | ||
| Q1 24 | -132.6% | -38.2% |
| Q4 25 | 0.0% | 3.5% | ||
| Q3 25 | 0.0% | 1.9% | ||
| Q2 25 | 0.0% | 4.6% | ||
| Q1 25 | 0.0% | 1.5% | ||
| Q4 24 | 0.2% | 2.1% | ||
| Q3 24 | 0.0% | 3.1% | ||
| Q2 24 | 0.0% | 4.4% | ||
| Q1 24 | 0.6% | 6.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -1.62× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KPTI
| Products | $32.1M | 94% |
| License And Other | $2.0M | 6% |
RXST
| Rxlal | $28.2M | 86% |
| LDD | $3.0M | 9% |
| Service Warranty Service Contracts And Accessories | $1.5M | 4% |
